Literature DB >> 26422187

The Association of Human Cytomegalovirus with Biomarkers of Inflammation and Immune Activation in HIV-1-Infected Women.

Nell S Lurain1, Barbara A Hanson1, Anna L Hotton2, Kathleen M Weber2, Mardge H Cohen2, Alan L Landay1.   

Abstract

Three groups of cytomegalovirus (CMV)-seropositive women (total n = 164) were selected from the Chicago Women's Interagency HIV-1 Study to investigate the association between CMV coinfection and immune activation: (1) HIV-1 viremic, (2) HIV-1 aviremic, and (3) HIV-1 uninfected. Quantitative measures of CMV serum IgG, CMV DNA, and serum biomarkers interleukin (IL)-6, soluble CD163 (sCD163), soluble CD14 (sCD14), and interferon gamma-induced protein (IP10) were obtained. Levels of CMV IgG and the serum biomarkers were significantly higher in the HIV-1 viremic group compared to the aviremic and uninfected groups (p < 0.001). No significant associations with CMV IgG levels were found for HIV-uninfected women. When each of the HIV-infected groups was analyzed, sCD14 levels in the viremic women were significantly associated with CMV IgG levels with p < 0.02 when adjusted for age, CD4 count, and HIV viral load. There was also a modest association (p = 0.036) with IL-6 from plasma and cervical vaginal lavage specimens both unadjusted and adjusted for CD4 count and HIV viral load. The association of CMV IgG level with sCD14 implicates the monocyte as a potential site for interaction of the two viruses, which eventually may lead to non-AIDS-defining pathological conditions.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26422187      PMCID: PMC4761818          DOI: 10.1089/AID.2015.0169

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  53 in total

1.  Cytomegalovirus DNA in semen and blood is associated with higher levels of proviral HIV DNA.

Authors:  Sara Gianella; Christy M Anderson; Milenka V Vargas; Douglas D Richman; Susan J Little; Sheldon R Morris; Davey M Smith
Journal:  J Infect Dis       Date:  2012-12-28       Impact factor: 5.226

Review 2.  Residual immune dysregulation syndrome in treated HIV infection.

Authors:  Michael M Lederman; Nicholas T Funderburg; Rafick P Sekaly; Nichole R Klatt; Peter W Hunt
Journal:  Adv Immunol       Date:  2013       Impact factor: 3.543

3.  Plasma levels of soluble CD14 independently predict mortality in HIV infection.

Authors:  Netanya G Sandler; Handan Wand; Annelys Roque; Matthew Law; Martha C Nason; Daniel E Nixon; Court Pedersen; Kiat Ruxrungtham; Sharon R Lewin; Sean Emery; James D Neaton; Jason M Brenchley; Steven G Deeks; Irini Sereti; Daniel C Douek
Journal:  J Infect Dis       Date:  2011-01-20       Impact factor: 5.226

4.  A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.

Authors:  A S Levey; J P Bosch; J B Lewis; T Greene; N Rogers; D Roth
Journal:  Ann Intern Med       Date:  1999-03-16       Impact factor: 25.391

5.  Retention and attendance of women enrolled in a large prospective study of HIV-1 in the United States.

Authors:  Nancy A Hessol; Kathleen M Weber; Susan Holman; Esther Robison; Lakshmi Goparaju; Christine B Alden; Naoko Kono; D Heather Watts; Niloufar Ameli
Journal:  J Womens Health (Larchmt)       Date:  2009-10       Impact factor: 2.681

6.  Shedding of HIV and human herpesviruses in the semen of effectively treated HIV-1-infected men who have sex with men.

Authors:  Sara Gianella; Davey M Smith; Milenka V Vargas; Susan J Little; Douglas D Richman; Eric S Daar; Michael P Dube; Fan Zhang; Christina C Ginocchio; Richard H Haubrich; Sheldon R Morris
Journal:  Clin Infect Dis       Date:  2013-04-17       Impact factor: 9.079

7.  CMV DNA levels and CMV gB subtypes in ART-naive HAART-treated patients: a 2-year follow-up study in The Netherlands.

Authors:  Valère J Goossens; Petra F Wolffs; Inge H van Loo; Cathrien A Bruggeman; Annelies Verbon
Journal:  AIDS       Date:  2009-07-17       Impact factor: 4.177

8.  Importance of cytomegalovirus viraemia in risk of disease progression and death in HIV-infected patients receiving highly active antiretroviral therapy.

Authors:  Jane R Deayton; Caroline A Prof Sabin; Margaret A Johnson; Vincent C Emery; Pauline Wilson; Paul D Griffiths
Journal:  Lancet       Date:  2004-06-26       Impact factor: 79.321

Review 9.  Cytomegalovirus, aging, and HIV: a perfect storm.

Authors:  Lisa Barrett; Keith R Fowke; Michael D Grant
Journal:  AIDS Rev       Date:  2012 Jul-Sep       Impact factor: 2.500

10.  Soluble CD14 is independently associated with coronary calcification and extent of subclinical vascular disease in treated HIV infection.

Authors:  Chris T Longenecker; Ying Jiang; Carl E Orringer; Robert C Gilkeson; Sara Debanne; Nicholas T Funderburg; Michael M Lederman; Norma Storer; Danielle E Labbato; Grace A McComsey
Journal:  AIDS       Date:  2014-04-24       Impact factor: 4.177

View more
  17 in total

Review 1.  Inflammation, immune activation, and cardiovascular disease in HIV.

Authors:  Eric Nou; Janet Lo; Steven K Grinspoon
Journal:  AIDS       Date:  2016-06-19       Impact factor: 4.177

2.  Elevated cytomegalovirus IgG antibody levels are associated with HIV-1 disease progression and immune activation.

Authors:  Eshan U Patel; Sara Gianella; Kevin Newell; Aaron A R Tobian; Allison R Kirkpatrick; Fredrick Nalugoda; Mary K Grabowski; Ronald H Gray; David Serwadda; Thomas C Quinn; Andrew D Redd; Steven J Reynolds
Journal:  AIDS       Date:  2017-03-27       Impact factor: 4.177

3.  Sexually transmitted infections and immune activation among HIV-infected but virally suppressed youth on antiretroviral therapy.

Authors:  Tanya L Kowalczyk Mullins; Su X Li; James Bethel; Maureen M Goodenow; Stephanie Hudey; John W Sleasman
Journal:  J Clin Virol       Date:  2018-02-07       Impact factor: 3.168

4.  High-fat diet exacerbates SIV pathogenesis and accelerates disease progression.

Authors:  Tianyu He; Cuiling Xu; Noah Krampe; Stephanie M Dillon; Paola Sette; Elizabeth Falwell; George S Haret-Richter; Tiffany Butterfield; Tammy L Dunsmore; William M McFadden; Kathryn J Martin; Benjamin B Policicchio; Kevin D Raehtz; Ellen P Penn; Russell P Tracy; Ruy M Ribeiro; Daniel N Frank; Cara C Wilson; Alan L Landay; Cristian Apetrei; Ivona Pandrea
Journal:  J Clin Invest       Date:  2019-12-02       Impact factor: 14.808

5.  Human Cytomegalovirus Enhances Placental Susceptibility and Replication of Human Immunodeficiency Virus Type 1 (HIV-1), Which May Facilitate In Utero HIV-1 Transmission.

Authors:  Erica L Johnson; Sahithi Boggavarapu; Elan S Johnson; Asim A Lal; Parth Agrawal; Siddhartha Kumar Bhaumik; Kaja Murali-Krishna; Rana Chakraborty
Journal:  J Infect Dis       Date:  2018-09-22       Impact factor: 5.226

Review 6.  Chronic obstructive pulmonary disease in HIV.

Authors:  Katerina Byanova; Ken M Kunisaki; Joshua Vasquez; Laurence Huang
Journal:  Expert Rev Respir Med       Date:  2020-11-23       Impact factor: 3.772

Review 7.  Activated T-effector seeds: cultivating atherosclerotic plaque through alternative activation.

Authors:  Maria M Xu; Patrick A Murphy; Anthony T Vella
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-03-29       Impact factor: 5.125

8.  Cytomegalovirus and paediatric HIV infection.

Authors:  Jennifer A Slyker
Journal:  J Virus Erad       Date:  2016-10-05

9.  Cytomegalovirus-specific T-cells are associated with immune senescence, but not with systemic inflammation, in people living with HIV.

Authors:  Vibe Ballegaard; Peter Brændstrup; Karin Kaereby Pedersen; Nikolai Kirkby; Anette Stryhn; Lars P Ryder; Jan Gerstoft; Susanne Dam Nielsen
Journal:  Sci Rep       Date:  2018-02-28       Impact factor: 4.379

10.  Blood-Brain Barrier Impairment in Patients Living with HIV: Predictors and Associated Biomarkers.

Authors:  Giulia Caligaris; Mattia Trunfio; Valeria Ghisetti; Jessica Cusato; Marco Nigra; Cristiana Atzori; Daniele Imperiale; Stefano Bonora; Giovanni Di Perri; Andrea Calcagno
Journal:  Diagnostics (Basel)       Date:  2021-05-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.